Dobutamine indications and usage: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
Line 9: | Line 9: | ||
:*Inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. | :*Inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. | ||
In patients who have [[atrial fibrillation]] with rapid ventricular response | In patients who have [[atrial fibrillation]] with rapid ventricular response: | ||
:*A '''[[digitalis]] preparation should be used prior to institution of therapy with dobutamine hydrochlorid'''e.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb842dc2-fb15-48f9-e4b1-ea4280db0199 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} |
Revision as of 22:34, 10 February 2014
Dobutamine |
---|
DOBUTamine® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Contraindications |
Warnings and Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
How Supplied/Storage and Handling |
Labels and Packages |
Clinical Trials on Dobutamine |
ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Indications And Usage
Dobutamine injection is indicated when parenteral therapy is necessary for:
- Inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
In patients who have atrial fibrillation with rapid ventricular response:
References
Adapted from the FDA Package Insert.